氯沙坦钾联合益肾化湿颗粒对慢性肾炎患者血浆蛋白浓度和IL1IL6IL13水平影响.docVIP

氯沙坦钾联合益肾化湿颗粒对慢性肾炎患者血浆蛋白浓度和IL1IL6IL13水平影响 　　摘 要 目的：研究氯沙坦钾联合益肾化湿颗粒对慢性肾炎患者尿蛋白浓度和IL-1、IL-6、IL-13水平的影响。方法：回顾性分析我院收治的59例慢性肾炎患者，按照给药方法分为对照组29例和观察组30例，对照组给予50 mg/d的氯沙坦钾，1次/d，观察组在此基础上再给予益肾化湿颗粒，3次/d，10 g/次。两组患者的疗程均为12周。观察治疗前后患者的血浆蛋白浓度、尿蛋白浓度和IL-1、IL-6、IL-13的水平变化，并分别记录其不良反应发生率。结果：经过治疗，观察组的尿蛋白浓度比对照组低（P0.05）。结论：氯沙坦钾联合益肾化湿颗粒治疗慢性肾炎的疗效更好，能有效增加血浆蛋白含量，减少尿蛋白，降低血清IL-1、IL-6、IL-13的水平，不良反应较少。 　　关键词 氯沙坦钾 慢性肾炎 血浆蛋白 白介素 　　中图分类号：R286； R692.3 文献标识码：B 文章编号：1006-1533（2016）19-0034-04 　　Effect of losartan potassium combined with Yishenhuashi on the levels of plasma protein， IL-1， IL-6 and IL-13 in the patients with chronic glomerulonephritis* 　　NI Zhigang** 　　（Department of Nephrology， The People’s Hospital of Yingtan City， Yingtan 335000， China） 　　ABSTRACT Objective： To evaluate the effect of losartan potassium combined with yishenhuashi on the levels of urine protein， IL-1， IL-6 and IL-13 in the patients with chronic glomerulonephritis. Methods： Fifty-nine cases of patients with chronic glomerulonephritis were retrospectively analyzed and divided into a control group （29 cases， treated with losartan potassium 50 mg/d qd） and an observation group （30 cases， treated with losartan potassium combined with yishenhuashi 10 g bid） and the treatment was lasted for 12 weeks. The changes of the concentrations of plasma and urine proteins and the levels of IL-1， IL-6 and IL-13 were observed before and after treatment， meanwhile the incidence of adverse reactions was recorded. Results： After treatment， the levels of urine protein were lower and the levels of plasma protein， IL-6 and IL-13 were higher in the observation group than in the control group （P0.01）. The IL-1 levels in both groups were reduced but did not show significant differences between two group. Conclusion： Losartan potassium combined with yishenhuashi has better efficacy with lower adverse reactions in the treatment of chronic glomerulonephritis， can effectively increase the plasma protein contents and reduce IL-1、IL-6 and IL-13 leve